急诊集束化治疗急性心力衰竭患者的疗效

目的:探讨急诊集束化治疗急性心力衰竭患者的影响。方法:选取急性心力衰竭患者100例,实施信封随机化方式分为对照组和观察组,各50例组,对照组采用常规急诊治疗方案,观察组采用急诊集束化干预。结果:观察组患者左心室舒张早期最大血流(E峰)、左心室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、动脉血氧分压(PaO_2)、收缩压(SBP)、呼吸(RR)、氧饱和度(SaO_2)、1秒用力呼气量(FEV_1)、最大肺活量(FVC)、FEV_1/FVC、气短缓解时间、不良事件发生率、气管插管率、总有效率均优于对照组(均P0.05)。结论:急诊集束化治疗用于急性心力衰竭患者效果显著,能降低气管插管率,提高患者疗效,改善患者心肺功能。     

,副主任医师,主要从事重症医学科医疗工作,研究方向：血流动力学监护治疗及休克抢救,电话：18678186858,邮箱：doctorwangicu@163.com,邮编：255036,地址：山东省淄博市张店区共青团西路54号淄博市中心医院重症医学科

【】：目的：探索急诊集束化治疗AHF患者的疗效及对其气管插管率和心肺功能的影响。方法：选取2016年10月22日至2017年10月22日期间我院急性心力衰竭100例患者(实施信封随机分组模式),对照组的50例患者进行常规急诊治疗方案干预,观察组的50例患者进行急诊集束化干预。结果：观察组患者E峰(69.17±6.54)cm/s、LVEF(46.41±1.89)%、LVESD(47.64±2.68)mm、LVEDD(58.59±3.84)mm、PaO2(95.32±5.46)mmHg、SBP(124.39±4.18)mmHg、RR(19.86±1.41)次/min、SaO2(96.87±2.41)%、FEV₁(3.10±0.12)L、FVC(30.41±7.35)L、FEV1/FVC(82.86±3.46)%、气短缓解时间(4.17±1.52)h、不良事件发生率(2.00%)、气管插管率(4.00%)、总有效率(98.00%)均优于对照组(P＜0.05)。结论：对AHF患者实施急诊集束化干预效果显著,能够改善心肺功能,降低气管插管率。     

法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭的临床疗效

目的探讨法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭的临床疗效及安全性。方法选取100例慢性充血性心力衰竭患者为研究对象,按随机数字表法分为观察组和对照组,各50例。对照组患者给予厄贝沙坦治疗,观察组患者给予法莫替丁联合厄贝沙坦治疗;对比分析两组患者临床治疗效果、治疗前后超声心动图相关指标和血压的改善情况,以及不良反应发生情况。结果观察组治疗总有效率高于对照组(P0.05);治疗后的左心室舒张末期内径(LVED)、左心室收缩末期内径(LVES)、舒张压和收缩压均低于对照组的(P0.05);治疗后的左心室射血分数(LVEF)高于对照组(P0.05)。结论法莫替丁联合厄贝沙坦治疗慢性充血性心力衰竭,安全性好,临床治疗效果好,值得临床应用。     

缬沙坦联合卡维地洛对心力衰竭患者心功能的影响

目的观察缬沙坦联合卡维地洛对慢性充血性心力衰竭患者心功能的影响。方法将57例慢性充血性心力衰竭患者随机分成两组。对照组给予常规治疗;研究组在此基础上加用缬沙坦和卡维地洛。比较两组治疗前后心率、收缩压、症状评分、左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）和左心室射血分数（LVEF）。结果对照组治疗后心率显著下降,LVEF显著改善（P〈0.05）;研究组治疗后心率、收缩压、症状评分、LVEDD、LVESD等指标值均显著下降（P〈0.05）,LVEF亦显著改善（P〈0.05）,且与对照组比较差异均有统计学意义（P〈0.05）。结论缬沙坦联合卡维地洛能有效改善慢性充血性心力衰竭患者的心功能,并逆转左心室重塑。     

丹参酮ⅡA磺酸钠对急性心力衰竭患者血流动力学和血管内皮功能的影响

目的探讨丹参酮ⅡA磺酸钠对急性心力衰竭患者血流动力学和血管内皮功能的影响。方法选取2012年东风总医院收治的急性心力衰竭患者98例,按照随机数字表法分为对照组与观察组,每组49例。对照组患者在常规治疗基础上给予美托洛尔治疗,观察组患者在对照组治疗基础上给予丹参酮ⅡA磺酸钠治疗;7 d为1个疗程,两组患者均连续治疗两个疗程。比较两组患者治疗前和治疗24 h后血流动力学指标〔中心静脉压(CVP)、肺循环阻力(PVR)、体循环阻力(SVR)、平均肺动脉压(MPAP)〕,治疗前后心功能指标〔左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)、每搏输出量(SV)、左心室射血分数(LVEF)〕和血管内皮功能指标〔内皮素1(ET-1)和一氧化氮(NO)〕,临床疗效及治疗期间不良反应发生情况。结果治疗前两组患者CVP、PVR、SVR、MPAP比较,差异无统计学意义(P0.05);治疗24 h后观察组患者CVP、PVR、SVR、MPAP低于对照组(P0.05)。两组患者治疗前后LVEDD、LVESD及治疗前SV、LVEF比较,差异无统计学意义(P0.05);治疗后观察组患者SV和LVEF高于对照组(P0.05)。治疗前两组患者血浆ET-1和NO水平比较,差异无统计学意义(P0.05);治疗后观察组患者血浆ET-1水平低于对照组,血浆NO水平高于对照组(P0.05)。观察组患者临床疗效优于对照组(P0.05);治疗期间两组患者均未出现严重不良反应。结论丹参酮ⅡA磺酸钠治疗急性心力衰竭的临床疗效确切,能有效改善急性心力衰竭患者血流动力学及血管内皮功能,且安全性较高。     

早期应用替罗非班在经皮冠状动脉介入治疗急性冠脉综合征的疗效评价

目的探讨急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)过程中加入替罗非班治疗的可行性和安全性。方法选取我院急诊就诊的120例急性冠脉综合征患者随机分为对照组60例(入院后立即急诊行PCI)和观察组60例(在给予PCI的过程中给予替罗非班治疗),比较两组患者术后心功能改善情况及术后住院期间不良事件的发生情况。结果观察组患者心功能指标(左心室射血分数、左心室舒张末期内径和左心室收缩末期内径)明显优于对照组,差异均有统计学意义(P0.05);对照组患者住院期间不良事件发生率明显高于观察组,差异有统计学意义[20%(12/60)与3.3%(2/60),P0.05]。结论急性冠脉综合征患者PCI时静脉滴注替罗非班显著改善患者的心脏功能和降低患者术后并发症。     

急诊集束化治疗急性心力衰竭的临床效果研究

目的分析急诊集束化治疗急性心力衰竭患者的效果及对心肺功能的影响。方法此次研究涉及的患者为90例,入院治疗时间为2016年9月~2017年9月,分为观察组和对照组,对照组治疗方法为常规急诊治疗,观察组在对照组的基础上实施急诊集束化治疗。结果两组患者治疗前动脉血氧饱和度、呼吸、收缩压以及动脉血氧分压无差异,治疗后观察组患者的数据明显优于于对照组,同时观察组气短缓解时间、住院时间以及急诊治疗时间明显比对照组短,P0.05。结论急性心力衰竭的患者,采用急诊集束化治疗的效果较为理想,能有效的提高患者心肺功能,快速改善患者的临床症状,缩短其治疗时间,保证患者健康,具有非常重要的临床意义。     

静脉滴注新活素治疗急性心力衰竭的疗效观察

目的探讨静脉滴注新活素(rhBNP)在治疗急性心力衰竭中的应用效果。方法选取2011年6—2011年10月住院的急性心力衰竭患者40例,随机分为两组(试验组、对照组)。试验组在抗心衰治疗的基础上应用新活素,对照组采用常规治疗方法。观察两组患者在用药前后呼吸困难、临床症状改善程度及相关血流动力学指标的变化,并对其进行比较。结果试验组患者治疗后临床症状的好转程度及左室射血分数(LVEF)值明显高于对照组(P<0.05),而两组之间心率、血压和左心室舒张末期内径(LVDD)改变比较无统计学意义(P>0.05)。结论静脉滴注新活素对缓解急性心力衰竭患者的临床症状和改善血流动力学指标有较明显的作用。     

急诊经皮冠状动脉介入术与静脉溶栓治疗急性心肌梗死的临床疗效及安全性比较

目的比较急诊经皮冠状动脉介入术(PCI)与静脉溶栓治疗急性心肌梗死(AMI)的临床疗效及安全性。方法选取2015年5月—2016年3月荆州市监利县人民医院心血管内科收治的AMI患者68例,采用随机数字表法分为对照组和观察组,每组34例。对照组患者给予静脉溶栓治疗,观察组患者行急诊PCI。比较两组患者心肌梗死溶栓试验(TIMI)血流分级,治疗前后左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF),随访1年期间不良心血管事件(心绞痛、心力衰竭、心源性死亡、再梗死)发生情况。结果观察组患者TIMI血流分级优于对照组(P0.05)。两组患者治疗前LVESD、LVEDD、LVEF比较,差异无统计学意义(P0.05);观察组患者治疗后LVESD、LVEDD均低于对照组,LVEF高于对照组(P0.05)。观察组患者随访期间不良心血管事件发生率低于对照组(P0.05)。结论与静脉溶栓治疗相比,急诊PCI治疗AMI的临床疗效更好、安全性更高。     

缬沙坦对急性冠脉综合征患者脑钠肽及高敏C反应蛋白的影响

目的:观察急性冠脉综合征患者缬沙坦治疗前后血浆脑钠肽(BNP)及高敏C反应蛋白(hsCRP)的变化,探讨缬沙坦抑制心室重构的作用机制.方法:急性冠脉综合征患者66例(急性心肌梗死43例,不稳定性心绞痛23例),随机分为治疗组(n=32)和对照组(n=34),分别检测两组治疗前、治疗1个月、治疗6个月,血浆BNP、hsCRP水平及心室结构功能的变化.结果:治疗后治疗组、对照组的急性心肌梗死患者、不稳定性心绞痛患者血浆BNP和hsCRP水平均呈下降趋势,治疗组治疗1个月下降明显、治疗6个月降低速度减慢,治疗组治疗1个月、6个月与同时间段对照组相比下降,对照组、治疗组与同组前一时间段相比亦下降,差异均有统计学意义(P<0.05～0.01).治疗1个月,两组患者左心室射血分数、左心室收缩末期内径及左心室舒张末期内径均无明显变化(P>0.05);治疗6个月,治疗组左心室射血分数较对照组明显升高(P<0.01),左心室收缩末期内径及心室舒张末期内径较对照组明显减小(P均<0.01),差异均有统计学意义.结论:血管紧张素Ⅱ受体拮抗剂缬沙坦能够抑制急性冠脉综合征患者血浆BNP及hsCRP的分泌,降低炎性反应,抑制心室重构.改善心功能.     

血小板微粒与急性冠脉综合征危险分层及临床预后的关系

目的 :评价循环血小板微粒(PMPs)与急性冠脉综合征(ACS)危险分层及临床预后的关系。方法:选取53例ACS患者为ACS组,招募同期就诊的稳定性心绞痛(SA)及体检的非冠心病(CAD)患者共53例为对照组。所有受试者入院即刻检测循环PMPs水平,同时随访ACS患者出院后1个月内发生主要不良心血管事件(MACE)情况。分析PMPs在各组及亚组间差异性。结果:①PMPs水平在急性心肌梗死(AMI)亚组(12.78%±3.61%)最高,不稳定性心绞痛(UA)亚组(8.64%±5.29%)PMPs水平显著高于SA(4.27%±2.45%)及非CAD亚组(3.55%±1.81%);②高危亚组患者PMPs水平显著高于中危及低危亚组(P0.05);③发生MACE的ACS患者入院时PMPs水平显著高于非MACE患者(13.53%±3.54%vs 7.57%±1.69%,P0.05)。结论:PMPs是潜在的评估ACS疾病病情与近期临床预后的标记物。     

21例多发性骨髓瘤分子遗传学异常的FISH检测的意义

目的：为探讨间期荧光原位杂交（FISH）在检测多发性骨髓瘤（MM）间期细胞13q14缺失、1q21、p53缺失以及免疫球蛋白重链（IgH）基因重排中的意义。方法：采用组合探针（1q21/RB1、D13S319/p53、IgH）对21例MM患者骨髓进行FISH检测,分析其分子遗传学异常,比较其与常规染色体检查及临床指标的相关性。结果：21例MM患者中,19例（90.48%）检测出1种或1种以上的细胞遗传学异常,15例（71.43%）同时检测出2种及以上的异常。其异常比例从高到低分别为：＋1异常（66.67%）,IgH基因重排（57.14%）,13号染色体缺失（47.62%）和p53基因丢失（23.81%）。3例（14.29%）通过G-显带常规染色体检查发现异常,与FISH比较两者差异有统计学意义（P〈0.01）。结论：＋1、IgH基因重排及13q14缺失在MM中的发生率较高。FISH技术能提高MM分子遗传学异常的敏感性。     

Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities

Chromosomal abnormalities have major biologic and prognostic implications in leukemias. Cytogenetic information in typically hypoproliferative multiple myeloma (MM) is limited because of difficulties in obtaining analyzable metaphases. In this study, karyotypes and other known prognostic factors were analyzed in 155 newly diagnosed MM patients, entered on an intensive treatment program with two autotransplants. Complete remission (CR), event-free (EFS) and overall survival (OS) were analyzed using standard statistical methods. Abnormal cytogenetics were found in 39% of patients and were associated with a significantly lower CR rate (27% v 48%; P = .008). EFS and OS were inferior in patients with either partial or complete deletion of chromosome 13 or 11q abnormalities ("unfavorable" karyotype) when compared with the remaining patients (P < .001) who, as a group, had a similar prognosis irrespective of cytogenetic findings, ie, inevaluable, normal, or abnormal but without an "unfavorable" karyotype. The patients with abnormalities of both chromosomes 11 and 13 had a dismal prognosis with median EFS and OS of only 11 and 12 months, respectively. Significant associations were noted between an "unfavorable" karyotype and IgA isotype, elevated levels of beta-2 microglobulin (B2M, > or = 3 mg/L) and age > 60 years. On multivariate regression analysis, the absence of an "unfavorable" karyotype was the most significant variable associated with prolonged EFS and OS (P = .0001 and .0002, respectively). Other independent favorable variables were age less than 60 years, C-reactive protein (CRP) < or = 0.4 mg/dL and bone marrow plasmacytosis < or = 50% before treatment. On a multivariate analysis without cytogenetics, these same three standard parameters were identified as the only favorable variables. Patients not having all three standard favorable variables had a significantly lower CR rate (P = .03), EFS (P = .0001), and OS (P = .002) if an unfavorable karyotype was detected. We conclude that, in this program of uniformly treated MM patients, a poor prognosis was associated predominantly with abnormalities of chromosomes 11 and 13.     

Fluorescent in situ hybridization studies in multiple myeloma

Abstract

Conventional cytogenetic analysis and fluorescence in situ hybridization (FISH) results of bone marrow samples of 36 multiple myeloma (MM) patients at the time of diagnosis have been evaluated. Three probes for chromosome 13q (RB1, D13S319, D13S25), one for 14q32 (IgH) and one for 17p13 (p53) have been used for hybridization with fixed cells. Twenty patients (55·5%) had normal karyotypes, whereas eight (22·2%) had numerical or structural chromosomal abnormalities. We did not find metaphases for chromosome analysis in eight (22·2%) patients. Fluorescence in situ hybridization analyses revealed at least one or more abnormal results in 25 (69·5%) cases, whereas 11(30·5%) cases had no abnormal findings. 14q32 rearrangement was the most common finding in FISH analyses and has been detected in 21 cases (58·3%). 13q deletion and 17p deletion have been detected in 11 (30·5%) and 5 (13·9%) cases, respectively. Fluorescence in situ hybridization studies including 14q32 and 17p13 chromosome regions may yield quite significant results during clinical follow-up of MM.     

The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma

Aneuploid is ubiquitous in multiple myeloma (MM), and 4 cytogenetic subcategories are recognized: hypodiploid (associated with a shorter survival), pseudodiploid, hyperdiploid, and near-tetraploid MM. The hypodiploid, pseudodiploid, and near-tetraploid karyotypes can be referred to as the nonhyperdiploid MM. Immunoglobulin heavy-chain (IgH) translocations are seen in 60% of patients. We studied the relation between aneuploidy and IgH translocations in MM. Eighty patients with MM and abnormal metaphases were studied by means of interphase fluorescent in situ hybridization (FISH) to detect IgH translocations. We also studied a second cohort of 199 patients (Eastern Cooperative Oncology Group [ECOG]) for IgH translocations, chromosome 13 monosomy/deletions (Delta13), and ploidy by DNA content. Mayo Clinic patients with abnormal karyotypes and FISH-detected IgH translocation were more likely to be nonhyperdiploid (89% versus 39%, P <.0001). Remarkably, 88% of tested patients with hypodiploidy (16 of 18) and 90% of tested patients with tetraploidy (9 of 10) had an IgH translocation. ECOG patients with IgH translocations were more likely to have nonhyperdiploid MM by DNA content (68% versus 21%, P <.001). This association was seen predominantly in patients with recurrent chromosome partners to the IgH translocation (11q13, 4p16, and 16q23). The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter.     

Molecular cytogenetic aberrations in 21 Chinese patients with plasma cell leukemia

Plasma cell leukemia (PCL) is a rare malignant plasma cell disorder. Cytogenetic studies performed on plasma cell disorders are scarce and difficult because of the low proliferation rate of plasma cells (PCs). Fluorescence in situ hybridization (FISH) analysis is an attractive alternative for evaluation of chromosomal changes in PCL. To explore the molecular cytogenetic abnormalities in Chinese patients with PCL, interphase FISH studies with three probes for the regions containing 13q14.3 (D13S319), 14q32 (IGHC/IGHV) and 1q12(CEP1) were retrospectively performed in 21 PCL patients. FISH with LSI IGH/CCND1 and LSI IGH/FGFR3 probes were used to detect t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with 14q32 rearrangement. Among 21 PCL patients, molecular cytogenetic aberrations were found in 18 (81.8%) patients, four (19.0%) patients simultaneously had 13q14 deletion, illegitimate IgH translocation and 1q abnormality. 13q14 deletion was detected in 13 (61.9%) cases and illegitimate 14q32 rearrangement in 16 (76.2%) including six with t(11;14) and three with t(4;14). Chromosome 1 abnormality was found in seven (33.3%) patients, one with deletion of 1q, six with at least three copies amplifications of 1q12 (Amp1q12). 14q32 rearrangement and 13q14 deletion were found concurrently in 11 (52.4%) cases. It was showed that most PCL had chromosomal abnormalities, 14q32 rearrangement, 13q14 deletion and chromosome 1 abnormality are the frequent abnormalities, and over half of the 14q32 rearrangement were t(11;14) or t(4;14). t(4;14) and 13q14 deletion were correlated in PCL. FISH is a highly sensitive technique at detecting molecular cytogenetic aberrations in PCL and should be used in the routine evaluation of PCL.     

Correlation between cytogenetic abnormalities and disease characteristics in multiple myeloma: monosomy of chromosome 13 and structural abnormalities of 11q are associated with a high percentage of S-phase plasma cells

BACKGROUND AND OBJECTIVES: Cytogenetic studies in multiple myleoma (MM) are limited by the difficulties in obtaining metaphases that can be investigated and few studies have analyzed the relationship between cytogenetics and clinical disease characteristics. The aim of our study was to analyze the recurrent cytogenetic changes in MM and to correlate them with clinical and biological characteristics including the percentage of S-phase plasma cells (PCs). DESIGN AND METHODS: Chromosomal abnormalities were analyzed in 86 patients with MM. In all patients, two types of cultures (5 d culture with interleukin-4 and unstimulated 72 h culture) were used for cytogenetic analysis. DNA content analysis (ploidy and cell cycle analysis) together with the most relevant clinical and biological disease features were studied. RESULTS: Cytogenetic analysis was successful in 72 of the 86 patients (84%). Forty-seven patients (65%) had an abnormal karyotype. The most frequent trisomies involved chromosomes 3, 5, 9, 11, 15, 19, 22, 1, 7, 17, 18, and 21, and monosomies affected chromosomes 13 and 8, while structural changes involved chromosomes 1, 11, 14q32, 4p16 and 16q22-23. Patients with abnormal karyotype displayed a poor performance status, advanced stage, anemia and a high percentage of bone marrow plasma cells. In addition, MM patients with -13/13q- and 11q abnormalities showed a significantly higher proportion of S-phase PCs (p=0.02). INTERPRETATION AND CONCLUSIONS: In summary, our study shows a relationship between unfavorable cytogenetics (-13/13q-/11q abnormalities) and a high percentage of S-phase PCs, a well-known adverse prognostic factor.     

Frequency and prognostic value of chromosome abnormalities in multiple myeloma

Chromosomal aberrations have been shown to significantly affect survival in multiple myeloma (MM), but few cytogenetic analyses among Japanese MM patients have been reported. Using a commercial laboratory, we performed interphase fluorescent in situ hybridization (FISH), as well as a conventional metaphase cytogenetic study (G-banding), among 106 of 131 patients between April 1997 and February 2007. Karyotype abnormalities were found in 21.2% (21 of 99 patients). Del(13q), del(17p), del(11q), t(11;14) and t(4;14) were detected by FISH in 36.0% (31/86), 24.7% (19/77), 7.6% (5/64), 18.2% (12/66) and 10.4% (7/67) of patients, respectively. The prevalence of abnormalities detected by G-banding was lower than that reported in European countries, but when compared with FISH studies, no difference was observed. Prognostic analyses of patients with these abnormal chromosomes revealed that those with abnormal karyotype and del(13q), t(4;14), as detected by FISH, had significantly poorer survival. This study suggests that the prevalence of chromosome abnormalities among Japanese patients is similar to that for European populations, and that chromosome studies by G-banding and FISH are essential to predict survival.     

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level

Although most multiple myeloma (MM) cases are characterized by the detection of a monoclonal immunoglobulin in the serum, about 15% of the patients present only immunoglobulin light chains, detected either in the urine or serum or both. These patients are designated as having light-chain (LC) MM. Using fiber-fluorescent in situ hybridization, and in contrast to patients and myeloma cell lines secreting heavy chains (who presented a legitimate functional IgH rearrangement in every case), LC MM never displayed a functional IgH recombination. Interestingly, most LC MM cases presented one IgH allele with a germline configuration (including the DJ region), the second allele being usually involved in an illegitimate recombination. Of note, most of these translocations occurred close to (or at) switch regions, even though in some cases, breakpoints involving nonswitch regions were observed. Thus, this study clearly showed that LC MM is due to the absence of legitimate IgH rearrangement at the DNA level, reflecting possible abnormalities in the IgH gene recombinations during B-cell maturation. Furthermore, it showed that this defect did not prevent the activation of the switch process because most of 14q32 translocations observed in LC MM occurred at switch regions.     

A Retrospective Analysis of Cytogenetic and Clinical Characteristics in Patients With Multiple Myeloma

BackgroundCytogenetic alterations in patients with multiple myeloma (MM) represent important risk factors in terms of prognosis. In this study, the impact of the cytogenetic aberrations of MM on patient clinical features and outcome was investigated.MethodsConventional cytogenetic analysis with R-banding technique and molecular cytogenetic characterization by interphase fluorescence in situ hybridization (FISH) were used to detect aberrant chromosomal arrangements, including 17p13 and 13q14 deletions, 14q32 rearrangement and 1q21 amplification, in bone marrow nucleated cells from 65 patients.ResultsAbout 16.9% of patients showed aberrations by conventional cytogenetic analysis, whereas 49.2% of patients showed aberrations by interphase FISH analysis. Abnormalities of 13q14, 1q21, 14q32 and 17p13 were detected in 27.7%, 13.8%, 16.9% and 29.2%, respectively. Patients with a 13q14 deletion or combined with 17p13 deletion frequently had a late stage of the disease, and tended to have elevated serum levels of β₂ microglobulin and lower levels of albumin. The progression-free survival and overall survival of FISH-positive patients were lower than for those without detectable abnormalities, especially in the conventional chemotherapy arm.ConclusionsThese findings demonstrate that myeloma cells are prone to exhibiting a complex aberration and that FISH is superior to conventional cytogenetic analysis with a higher detection rate of chromosomal abnormalities. Patients with a 17p13 or 13q14 deletion, 14q32 rearrangement and 1q21 amplification were more likely to have a poor prognosis for MM.